Published in Heart on September 04, 2006
Effect of Chronic Kidney Diseases on Mortality among Digoxin Users Treated for Non-Valvular Atrial Fibrillation: A Nationwide Register-Based Retrospective Cohort Study. PLoS One (2016) 0.89
Atrial fibrillation: mechanisms, therapeutics, and future directions. Compr Physiol (2015) 0.77
Digoxin Use and Adverse Outcomes in Patients With Atrial Fibrillation. Medicine (Baltimore) (2016) 0.76
New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant. J Interv Card Electrophysiol (2008) 0.76
Prospective observational studies of the management and outcomes in patients with atrial fibrillation: A systematic review. J Saudi Heart Assoc (2012) 0.75
Atrial fibrillation: Rate control and digoxin. BMJ (2007) 0.75
A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med (2002) 16.31
A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med (2002) 8.37
The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol (2004) 5.05
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation (2004) 4.04
Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet (2000) 3.36
Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol (2003) 2.73
Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J (2005) 2.31
Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J (2005) 2.28
Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol (2004) 2.10
Digoxin revisited. QJM (1998) 2.09
Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation (2004) 1.99
Relation between achieved heart rate and outcomes in patients with atrial fibrillation (from the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] Study). Am J Cardiol (2004) 1.97
Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J (2005) 1.71
Tachycardia-induced cardiomyopathy. Am J Med (2003) 1.66
Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol (1996) 1.62
Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation--results from the RAte Control versus Electrical cardioversion (RACE) study. Eur Heart J (2004) 1.54
Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann Intern Med (2004) 1.52
Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure? Am J Cardiol (2004) 1.41
Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation. Br Med J (Clin Res Ed) (1985) 1.30
Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol (1999) 1.21
Clinical outcomes after ablation and pacing therapy for atrial fibrillation : a meta-analysis. Circulation (2000) 1.19
What is meant by a "controlled" ventricular rate in atrial fibrillation? Br Heart J (1990) 1.14
Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. Eur Heart J (2003) 1.04
Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol (2003) 1.02
Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation (1986) 0.91
The evidence regarding the drugs used for ventricular rate control. J Fam Pract (2000) 0.90
Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Am Heart J (2002) 0.87
A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation. Eur Heart J (1988) 0.87
Usefulness of labetalol in chronic atrial fibrillation. Am J Cardiol (1990) 0.84
Final consensus statement of the Royal College of Physicians of Edinburgh Consensus Conference on atrial fibrillation in hospital and general practice, 3-4 September 1998. Br J Haematol (1999) 0.78
Control of heart rate versus rhythm in rheumatic atrial fibrillation: a randomized study. J Cardiovasc Pharmacol Ther (2004) 0.78
Fibrinogen: biochemistry, epidemiology and determinants. QJM (2003) 2.05
Antithrombotic therapy in hypertension: a Cochrane Systematic review. J Hum Hypertens (2005) 2.05
The Birmingham Rehabilitation Uptake Maximisation study (BRUM): a randomised controlled trial comparing home-based with centre-based cardiac rehabilitation. Heart (2008) 2.03
Cardiovascular risk in patients with sleep apnoea with or without continuous positive airway pressure therapy: follow-up of 4.5 million Danish adults. J Intern Med (2014) 1.86
Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM (2007) 1.76
A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost (2011) 1.62
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol (2012) 1.60
High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost (2012) 1.55
Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis. J Intern Med (2007) 1.53
Increased 5-year mortality in the migrant South Asian stroke patients with diabetes mellitus in the United Kingdom: the West Birmingham Stroke Project. Int J Clin Pract (2007) 1.50
Matrix metalloproteinases and their tissue inhibitors in hypertension-related pregnancy complications. J Hum Hypertens (2012) 1.49
Angiogenin: a review of the pathophysiology and potential clinical applications. J Thromb Haemost (2006) 1.45
Should oral glucose tolerance testing be mandatory following acute myocardial infarction? Int J Clin Pract (2007) 1.41
Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia (2006) 1.41
Obstructive sleep apnoea and metabolic syndrome: two sides of the same coin? J Hum Hypertens (2008) 1.39
Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. J Thromb Haemost (2010) 1.32
Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology. J Thromb Haemost (2011) 1.31
Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost (2011) 1.23
Peripheral vascular disease and Virchow's triad for thrombogenesis. QJM (2002) 1.19
Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur J Clin Invest (2003) 1.19
Ethnic differences in blood pressure and the prevalence of hypertension in England. J Hum Hypertens (2002) 1.12
The CD14++CD16+ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction. J Thromb Haemost (2012) 1.11
The potential impact of periodontal disease on general health: a consensus view. Curr Med Res Opin (2008) 1.09
Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. Br J Ophthalmol (2004) 1.07
Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart (2003) 1.06
Assessment of endothelial damage and dysfunction: observations in relation to heart failure. QJM (2003) 1.02
Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. Thromb Haemost (2013) 1.00
Circulating endothelial cells: markers of vascular dysfunction. Clin Lab (2005) 1.00
Biomarkers in atrial fibrillation: an overview. Int J Clin Pract (2013) 0.99
Quality of life in patients with silent atrial fibrillation. Heart (2001) 0.99
Lone atrial fibrillation - an overview. Int J Clin Pract (2013) 0.98
Women's reproductive health needs in Russia: what can we learn from an intervention to improve post-abortion care? Health Policy Plan (2007) 0.98
The role of omega-3 fatty acids in the secondary prevention of cardiovascular disease. QJM (2003) 0.96
Quality of life in adults with congenital heart disease. Heart (2002) 0.95
Retinal vein and artery occlusions: a risk factor for stroke in atrial fibrillation. J Thromb Haemost (2013) 0.95
Systolic vs diastolic blood pressure and the burden of hypertension. J Hum Hypertens (2002) 0.94
Factors predicting the development of metabolic syndrome and type II diabetes against a background of hypertension. Eur J Clin Invest (2005) 0.94
Lone atrial fibrillation: what is known and what is to come. Int J Clin Pract (2011) 0.94
Admissions with atrial fibrillation in a multiracial population in Kuala Lumpur, Malaysia. Int J Cardiol (2003) 0.93
Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels. Diabet Med (2005) 0.93
Compliance with pharmacological therapy in hypertension: can we do better, and how? J Hum Hypertens (2004) 0.92
Collateralization and the response to obstruction of epicardial coronary arteries. QJM (2004) 0.92
The endothelium and atrial fibrillation. The prothrombotic state revisited. Hamostaseologie (2008) 0.92
Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. Heart (2004) 0.91
Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay. Eur J Clin Invest (2003) 0.91
Blood pressure control in the setting of diabetes mellitus: new targets, new hope for improvement? J Hum Hypertens (2006) 0.91
Type 2 diabetes mellitus: a cardiovascular perspective. Int J Clin Pract (2005) 0.91
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J (2013) 0.91
White blood cell count and hypertension. J Hum Hypertens (2006) 0.90
A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990-1999. J Thromb Haemost (2006) 0.90
Circulating serum adiponectin levels in patients with coronary artery disease: relationship to atherosclerotic burden and cardiac function. J Intern Med (2008) 0.90
Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. BMJ (2011) 0.90
Depression, indirect clinical markers of cardiac disease severity, and mortality following myocardial infarction. Heart (2005) 0.89
Left ventricular ejection fraction: are the revised cut-off points for defining systolic dysfunction sufficiently evidence based? Heart (2008) 0.89
A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels. J Intern Med (2007) 0.89
Silent atrial fibrillation--another Pandora's box. Pacing Clin Electrophysiol (2000) 0.88
Psychological interventions for depression in heart failure. Cochrane Database Syst Rev (2005) 0.88
Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost (2013) 0.88
Soluble P-selectin and vascular endothelial growth factor in steady state sickle cell disease: relationship to genotype. J Thromb Thrombolysis (2007) 0.88
Dual chamber versus single chamber ventricular pacemakers for sick sinus syndrome and atrioventricular block. Cochrane Database Syst Rev (2004) 0.88
Atrial fibrillation as a risk factor for cognitive impairment: a semi-systematic review. QJM (2013) 0.87
Identification, diagnosis and assessment of atrial fibrillation. Heart (2006) 0.87
Oral antithrombotic therapy and gastrointestinal bleeding: the good, the bad and the ugly. Int J Clin Pract (2012) 0.87
Platelet P-selectin and platelet mass, volume and component in sickle cell disease: relationship to genotype. Thromb Res (2005) 0.87
A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy. Eur Heart J (2002) 0.87
Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. J Thromb Haemost (2012) 0.86
Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J (2003) 0.86
A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Blood Coagul Fibrinolysis (2003) 0.86
Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effects of antihypertensive therapy. J Intern Med (2004) 0.86
Ethnic differences in myocardial infarction in patients with hypertension: effects of diabetes mellitus. QJM (2008) 0.86
Plasma vascular endothelial growth factor, soluble VEGF receptor FLT-1, and von Willebrand factor in glaucoma. Br J Ophthalmol (2002) 0.86
Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity. J Intern Med (2005) 0.86
Localisation of members of the vascular endothelial growth factor (VEGF) family and their receptors in human atherosclerotic arteries. J Clin Pathol (2004) 0.85
Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest (2003) 0.85
The angiopoietin/Tie-2 system in proliferative sickle retinopathy: relation to vascular endothelial growth factor, its soluble receptor Flt-1 and von Willebrand factor, and to the effects of laser treatment. Br J Ophthalmol (2005) 0.85
Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populations. Atherosclerosis (2009) 0.85
Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost (2015) 0.84
Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study. Neth Heart J (2013) 0.84
The relationship of circulating endothelial cells to plasma indices of endothelial damage/dysfunction and apoptosis in acute coronary syndromes: implications for prognosis. J Thromb Haemost (2008) 0.84
Antithrombotic treatment in atrial fibrillation. Heart (2006) 0.84
Circulating levels of VEGF-A, VEGF-D and soluble VEGF-A receptor (sFIt-1) in human breast cancer. Int J Biol Markers (2004) 0.84
Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials. J Hum Hypertens (2005) 0.84
Secular trends in the cardiovascular risk profile and mortality of stroke admissions in an inner city, multiethnic population in the United Kingdom (1997-2005). J Hum Hypertens (2007) 0.84
Renin-angiotensin blockade in diabetic retinopathy. Int J Clin Pract (2011) 0.84
Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2013) 0.84
QT interval and QT dispersion measured with the threshold method depend on threshold level. Pacing Clin Electrophysiol (1998) 0.83
Brachial plexus injury as an unusual complication of coronary artery bypass graft surgery. Postgrad Med J (2003) 0.83
New insights into complement C3 and inflammation in hypertension. J Hum Hypertens (2007) 0.83
Differences between South Asians and White Europeans in five year outcome following percutaneous coronary intervention. Int J Clin Pract (2011) 0.83
Tissue inhibitor of metalloproteinse-1 is a marker of diastolic dysfunction using tissue doppler in patients with type 2 diabetes and hypertension. Eur J Clin Invest (2005) 0.83
Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. Thromb Haemost (2014) 0.83
The effects of exercise stress testing, diurnal variation and temporal decline on circulating progenitor cells. Thromb Haemost (2009) 0.83
Abnormal low-density lipoprotein subfraction profile in patients with untreated hypertension. QJM (2002) 0.83
Impact of vascular disease in predicting stroke and death in patients with atrial fibrillation: the Danish Diet, Cancer and Health cohort study. J Thromb Haemost (2011) 0.83